Navigation Links
Metamark Genetics, Inc. Announces New Chief Scientific Officer

CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Metamark Genetics, Inc., a privately held molecular diagnostics company developing innovative personalized medicine approaches to optimize cancer care, announced today the appointment of Peter Blume-Jensen, M.D., Ph.D. as Chief Scientific Officer.

Dr. Blume-Jensen joins Metamark with over 20 years of experience in cancer research and oncology drug discovery. From 2001 to 2008 Dr. Blume-Jensen was department head at EMD Serono, Inc. and later at Merck Research Laboratories, Merck & Co, Inc. where he established integrated oncology R&D programs linking therapeutics to patient responder populations. During his tenure he advanced a number of pre-clinical drug programs into the clinic, and provided translational support for clinical programs. Since 2008 he served as Exec. Dir., External Scientific Affairs and Vice President of Daiichi Sankyo Research Institute, Daiichi Sankyo Inc., was 'Therapeutic Area Advisor' for Oncology, and helped formulate a global oncology R&D strategy. Dr. Blume-Jensen's pioneering work on oncogenic signaling, disease mouse models, and more recently efficacy-predictive biomarkers for oncology therapeutics is highly cited. Dr. Blume-Jensen obtained his M.D. from Copenhagen, Denmark, his Ph.D. from Dr. Carl-Henrik Heldin's laboratory at the Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-Doctoral studies in Dr. Tony Hunter's laboratory at the Salk Institute, La Jolla, CA.

Kenneth E. Weg, Metamark's Chairman and CEO stated, "Metamark is very fortunate to have attracted a true leader in the personalized oncology movement to shepherd Metamark's ambitious Research and Development efforts. We welcome Dr. Blume-Jensen to the expanding Metamark team."

Dr. Blume-Jensen stated, "I am very excited about the innovative, function-driven Metamark platform and the opportunity to join the Metamark team to help catapult the launch of the first MetamarkDx™ Prognostic Assays. I am looking forward to applying my expertise in personalized oncology medicine and predictive biomarkers to help transform Metamark into the leading next generation molecular diagnostics company."

Cautionary Note Regarding Forward-Looking Statements

This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results, are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.   Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.  

SOURCE Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
2. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
3. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Anesiva Announces Second Quarter 2008 Financial Results and Update
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... announced today that they have entered into a multiyear collaboration to identify and ... researchers with additional tools for gene editing across all applications. , Under the ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... ... 2017 , ... Proscia Inc ., a data solutions ... “Pathology is going digital. Is your lab ready?” with Dr. Nicolas Cacciabeve, Managing ... how Proscia improves lab economics and realizes an increase in diagnostic confidence.* ...
Breaking Biology Technology:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being ... microbiome—the bacteria that live in and on the human body –and are ... The Microbiome ... the human microbiome, starting with the gut. The project's goal is to ... Photo credit: IBM ...
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
Breaking Biology News(10 mins):